Literature DB >> 30987856

Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus.

Jianghong Deng1, Nathalie E Chalhoub2, Catherine M Sherwin3, Caifeng Li4, Hermine I Brunner5.   

Abstract

Glucocorticoids are potent anti-inflammatory and immunosuppressant medications and remain the mainstay of systemic lupus erythematosus (SLE) therapy. The potency of a specific glucocorticoid, i.e., the dose of glucocorticoid that is required to produce a specific effect, is dependent on its pharmacokinetic (PK) and pharmacodynamic (PD) properties. In this review, we summarize the PK/PD properties of commonly used glucocorticoids in an attempt to better delineate their role in the management of children with childhood-onset SLE (cSLE). We also address glucocorticoid side effects as these play a major role when deciding on the dose, frequency, and duration of use. A better understanding of the pharmacology of glucocorticoids appears useful to achieve improved outcomes in the management of cSLE.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Childhood-onset systemic lupus erythematosus; Glucocorticoids; Pharmacodynamics; Pharmacokinetics

Mesh:

Substances:

Year:  2019        PMID: 30987856      PMCID: PMC6744986          DOI: 10.1016/j.semarthrit.2019.03.010

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  108 in total

1.  Therapeutic implications of non-genomic glucocorticoid activity.

Authors:  B J Lipworth
Journal:  Lancet       Date:  2000-07-08       Impact factor: 79.321

2.  Prednisone and prednisolone in the treatment of systemic lupus erythematous.

Authors:  E L DUBOIS
Journal:  J Am Med Assoc       Date:  1956-06-02

3.  European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative.

Authors:  Noortje Groot; Nienke de Graeff; Tadej Avcin; Brigitte Bader-Meunier; Paul Brogan; Pavla Dolezalova; Brian Feldman; Isabelle Kone-Paut; Pekka Lahdenne; Stephen D Marks; Liza McCann; Seza Ozen; Clarissa Pilkington; Angelo Ravelli; Annet van Royen-Kerkhof; Yosef Uziel; Bas Vastert; Nico Wulffraat; Sylvia Kamphuis; Michael W Beresford
Journal:  Ann Rheum Dis       Date:  2017-06-19       Impact factor: 19.103

4.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

Review 5.  It hasn't gone away: the problem of glucocorticoid use in lupus remains.

Authors:  Diane Apostolopoulos; Eric F Morand
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

6.  Fungus infection in steroid-treated systemic lupus erythematosus.

Authors:  V K Pillay; D M Wilson; T S Ing; R M Kark
Journal:  JAMA       Date:  1968-07-29       Impact factor: 56.272

7.  Treatment of systemic lupus erythematosus complicated by nephritis in children.

Authors:  W W Hagge; E C Burke; G B Stickler
Journal:  Pediatrics       Date:  1967-11       Impact factor: 7.124

8.  Clinicopathological correlations of paediatric lupus nephritis.

Authors:  Stephen D Marks; Neil J Sebire; Clarissa Pilkington; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2006-11-15       Impact factor: 3.714

9.  Glucocorticoid receptor beta splice variant expression in patients with high and low activity of systemic lupus erythematosus.

Authors:  Piotr Piotrowski; Michal Burzynski; Margarita Lianeri; Magdalenaa Mostowska; Mariusz Wudarski; Hanna Chwalinska-Sadowska; Pawel P Jagodzinski
Journal:  Folia Histochem Cytobiol       Date:  2007       Impact factor: 1.698

10.  Mood and Cognitive Changes During Systemic Corticosteroid Therapy.

Authors:  E Sherwood Brown; Patricia A. Chandler
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-02
View more
  5 in total

1.  Analysis of the safety and efficacy of tacrolimus combined with glucocorticoid in the treatment of lupus nephritis.

Authors:  Lu Li; Yong Du; Juan Ji; Ying Gao; Xiao-Qiang Shi
Journal:  Pak J Med Sci       Date:  2022 May-Jun       Impact factor: 2.340

2.  Lipidomics Revealed Aberrant Metabolism of Lipids Including FAHFAs in Renal Tissue in the Progression of Lupus Nephritis in a Murine Model.

Authors:  Changfeng Hu; Yu Du; Xiaofen Xu; Haichang Li; Qiao Duan; Zhijun Xie; Chengping Wen; Xianlin Han
Journal:  Metabolites       Date:  2021-02-27

Review 3.  Macrophage Polarization and Plasticity in Systemic Lupus Erythematosus.

Authors:  Mariame Mohamed Ahamada; Yang Jia; Xiaochuan Wu
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

4.  An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Vitor Cavalcanti Trindade; Magda Carneiro-Sampaio; Eloisa Bonfa; Clovis Artur Silva
Journal:  Paediatr Drugs       Date:  2021-07-10       Impact factor: 3.022

5.  International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis.

Authors:  Nathalie E Chalhoub; Scott E Wenderfer; Deborah M Levy; Kelly Rouster-Stevens; Amita Aggarwal; Sonia I Savani; Natasha M Ruth; Thaschawee Arkachaisri; Tingting Qiu; Angela Merritt; Karen Onel; Beatrice Goilav; Raju P Khubchandani; Jianghong Deng; Adriana R Fonseca; Stacy P Ardoin; Coziana Ciurtin; Ozgur Kasapcopur; Marija Jelusic; Adam M Huber; Seza Ozen; Marisa S Klein-Gitelman; Simone Appenzeller; André Cavalcanti; Lampros Fotis; Sern Chin Lim; Rodrigo M Silva; Julia Ramírez- Miramontes; Natalie L Rosenwasser; Claudia Saad-Magalhaes; Dieneke Schonenberg-Meinema; Christiaan Scott; Clovis A Silva; Sandra Enciso; Maria T Terreri; Alfonso-Ragnar Torres-Jimenez; Maria Trachana; Sulaiman M Al-Mayouf; Prasad Devarajan; Bin Huang; Hermine I Brunner
Journal:  Arthritis Rheumatol       Date:  2022-01-04       Impact factor: 10.995

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.